There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Viracta Therapeutics Inc. (VIRX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.04, or 2.22%, to $1.84. The Viracta Therapeutics Inc. has recorded 3,256 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.80 and fluctuated between $2.1099 as its day high and $1.7100 as its day low. The current market capitalization of Viracta Therapeutics Inc. is $62.77M. A total of 0.51 million shares were traded on the day, compared to an average of 179.90K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, VIRX has seen 4 BUY and 2 SELL insider trades, representing the acquisition of 45,269 and the disposition of 5,755 shares. Over the last 12 months, there were 16 BUYs and 10 SELLs from insiders. Insiders purchased 181,076 shares during that period but sold 49,539.
In the most recent transaction, Chevallard Daniel R. sold 3,599 shares of VIRX for 1.68 per share on Feb 27. After the transaction, the CFO and COO now owns 89,023 company shares. In a previous transaction on Feb 27, Rojkjaer Lisa sold 2,156 shares at 1.68 per share. VIRX shares that Chief Medical Officer owns now total 48,087.
Among the insiders who sold shares, Chevallard Daniel R. disposed of 3,532 shares on Nov 28 at a per-share price of $2.72. This resulted in the CFO and COO holding 85,733 shares of VIRX after the transaction. In another insider transaction, Rojkjaer Lisa sold 2,116 shares at $2.72 per share on Nov 28. Company shares held by the Chief Medical Officer now total 46,116.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for VIRX in the last 3 months, the mean price target is $14.80 with high estimates of $33.00 and low estimates of $7.00. In terms of 52-week highs and lows, VIRX has a high of $5.75 and a low of $0.88.
As of this writing, VIRX has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.32. The company reported an EPS of -$0.27 in the last quarter, which was 28.90% higher than expectations of -$0.38.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. VIRX’s latest balance sheet shows that the firm has $103.55M in Cash & Short Term Investments as of fiscal 2021. There were $5.48M in debt and $9.08M in liabilities at the time. Its Book Value Per Share was $1.19, while its Total Shareholder’s Equity was $94.37M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VIRX is Buy with a score of 4.75.